|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang B, Jiao J, Liu Y, Guo LX, Zhou B, Li
GQ, Yao ZJ and Zhou GB: Gefitinib analogue V1801 induces apoptosis
of T790M EGFR-harboring lung cancer cells by up-regulation of the
BH-3 only protein Noxa. PLoS One. 7:e487482012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kwon T, Rho JK, Lee JC, Park YH, Shin HJ,
Cho S, Kang YK, Kim BY, Yoon DY and Yu DY: An important role for
peroxiredoxin II in survival of A549 lung cancer cells resistant to
gefitinib. Exp Mol Med. 47:e1652015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Engelman JA and Jänne PA: Mechanisms of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
14:2895–2899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwak EL, Sordella R, Bell DW,
Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR,
Fidias P, Lynch TJ, et al: Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl
Acad Sci USA. 102:7665–7670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim Y, Ko J, Cui Z, Abolhoda A, Ahn JS, Ou
SH, Ahn MJ and Park K: The EGFR T790M mutation in acquired
resistance to an irreversible second-generation EGFR inhibitor. Mol
Cancer Ther. 11:784–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Finlay MR, Anderton M, Ashton S, Ballard
P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S,
Campbell A, et al: Discovery of a potent and selective EGFR
inhibitor (AZD9291) of both sensitizing and T790M resistance
mutations that spares the wild type form of the receptor. J Med
Chem. 57:8249–8267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perrotti D and Neviani P: Protein
phosphatase 2A: A target for anticancer therapy. Lancet Oncol.
14:e229–e238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seshacharyulu P, Pandey P, Datta K and
Batra SK: Phosphatase: PP2A structural importance, regulation and
its aberrant expression in cancer. Cancer Lett. 335:9–18. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schönthal AH: Role of serine/threonine
protein phosphatase 2A in cancer. Cancer Lett. 170:1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lv P, Wang Y, Ma J, Wang Z, Li JL, Hong
CS, Zhuang Z and Zeng YX: Inhibition of protein phosphatase 2A with
a small molecule LB100 radiosensitizes nasopharyngeal carcinoma
xenografts by inducing mitotic catastrophe and blocking DNA damage
repair. Oncotarget. 5:7512–7524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lucas CM, Harris RJ, Giannoudis A, Copland
M, Slupsky JR and Clark RE: Cancerous inhibitor of PP2A (CIP2A) at
diagnosis of chronic myeloid leukemia is a critical determinant of
disease progression. Blood. 117:6660–6668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Li W, Li L, Yu X, Jia J and Chen
C: CIP2A is over-expressed in acute myeloid leukaemia and
associated with HL60 cells proliferation and differentiation. Int J
Lab Hematol. 33:290–298. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tseng LM, Liu CY, Chang KC, Chu PY, Shiau
CW and Chen KF: CIP2A is a target of bortezomib in human triple
negative breast cancer cells. Breast Cancer Res. 14:R682012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Böckelman C, Hagström J, Mäkinen LK,
Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A and Haglund
C: High CIP2A immunoreactivity is an independent prognostic
indicator in early-stage tongue cancer. Br J Cancer. 104:1890–1895.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Böckelman C, Lassus H, Hemmes A, Leminen
A, Westermarck J, Haglund C, Bützow R and Ristimäki A: Prognostic
role of CIP2A expression in serous ovarian cancer. Br J Cancer.
105:989–995. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar
|
|
22
|
Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ,
Liu YQ, Pu JX, Xiao WL, Sun HD, et al: Overexpression and small
molecule-triggered downregulation of CIP2A in lung cancer. PLoS
One. 6:e201592011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie
J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a
diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion
protein and shows potent antitumor activity with low adverse
effects on t(8;21) leukemia in vitro and in vivo. Blood.
109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Wang Y, Wang S, Gao Y, Zhang X and
Lu C: Oridonin phosphate-induced autophagy effectively enhances
cell apoptosis of human breast cancer cells. Med Oncol. 32:3652015.
View Article : Google Scholar
|
|
25
|
Zhao Z and Chen Y: Oridonin, a promising
antitumor natural product in the chemotherapy of hematological
malignancies. Curr Pharm Biotechnol. 15:1083–1092. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang YY, Lv YF, Lu L and Cai L: Oridonin
inhibits mTOR signaling and the growth of lung cancer tumors.
Anticancer Drugs. 25:1192–1200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu B, Shen W, Liu X, Zhang T, Ren J, Fan Y
and Xu J: Oridonin inhibits BxPC-3 cell growth through cell
apoptosis. Acta Biochim Biophys Sin (Shanghai). 47:164–173. 2015.
View Article : Google Scholar
|
|
28
|
Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu
YP, Yu XJ, Zhang XD, Ming PH, Zhou GB, et al: The natural compound
magnolol inhibits invasion and exhibits potential in human breast
cancer therapy. Sci Rep. 3:30982013.PubMed/NCBI
|
|
29
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P, et al: Homoharringtonine
induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal
pathway in Gefitinib-resistant lung cancer cells. Sci Rep.
5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang
Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET
oncoprotein is associated with tumor progression and poor prognosis
in human non-small cell lung cancer. Oncotarget. 6:14913–14925.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao J, Liu X, Yang F, Liu T, Yan Q and
Yang X: By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM
inhibits breast cancer cell growth and metastasis. Oncotarget.
6:27187–27198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang XS, Liu SA, Liu JW and Yan Q:
Fucosyltransferase IV enhances expression of MMP-12 stimulated by
EGF via the ERK1/2, p38 and NF-κB pathways in A431 cells. Asian
Pacific journal of cancer prevention Asian Pac J Cancer Prev.
13:1657–1662. 2012. View Article : Google Scholar
|
|
33
|
Hofmann HS, Hansen G, Richter G, Taege C,
Simm A, Silber RE and Burdach S: Matrix metalloproteinase-12
expression correlates with local recurrence and metastatic disease
in non-small cell lung cancer patients. Clin Cancer Res.
11:1086–1092. 2005.PubMed/NCBI
|
|
34
|
Radisavljevic Z: AKT as locus of cancer
multidrug resistance and fragility. J Cell Physiol. 228:671–674.
2013. View Article : Google Scholar
|
|
35
|
Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM,
Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via
PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta
Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brodie SA, Li G, Harvey D, Khuri FR,
Vertino PM and Brandes JC: Small molecule inhibition of the
CHFR-PARP1 interaction as novel approach to overcome intrinsic
taxane resistance in cancer. Oncotarget. 6:30773–30786.
2015.PubMed/NCBI
|
|
37
|
Liu Y, Liu JH, Chai K, Tashiro S, Onodera
S and Ikejima T: Inhibition of c-Met promoted apoptosis, autophagy
and loss of the mitochondrial transmembrane potential in
oridonin-induced A549 lung cancer cells. J Pharm Pharmacol.
65:1622–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pritchard VL, Dimond L, Harrison JS,
Velázquez CC S, Zieba JT, Burton RS and Edmands S: Interpopulation
hybridization results in widespread viability selection across the
genome in Tigriopus californicus. BMC Genet. 12:542011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang S, Yu S, Shi W, Ge L, Yu X, Fan J and
Zhang J: Curcumin inhibits the migration and invasion of mouse
hepatoma Hca-F cells through down-regulating caveolin-1 expression
and epidermal growth factor receptor signaling. IUBMB Life.
63:775–782. 2011. View Article : Google Scholar
|
|
40
|
Hsieh CY, Tsai PC, Tseng CH, Chen YL,
Chang LS and Lin SR: Inhibition of EGF/EGFR activation with
naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of
MDA-MB-231 cells. Toxicol In Vitro. 27:1–10. 2013. View Article : Google Scholar
|
|
41
|
Hu Y, Chen F, Liu F, Liu X, Huang N, Cai
X, Sun Y, Li A and Luo R: Overexpression of TIP30 inhibits the
growth and invasion of glioma cells. Mol Med Rep. 13:605–612.
2016.PubMed/NCBI
|
|
42
|
Tsai JR, Liu PL, Chen YH, Chou SH, Cheng
YJ, Hwang JJ and Chong IW: Curcumin Inhibits non-small cell lung
cancer cells metastasis through the adiponectin/NF-κB/MMPs
signaling pathway. PLoS One. 10:e01444622015. View Article : Google Scholar
|
|
43
|
Hwang J, Kim Y, Kang HB, Jaroszewski L,
Deacon AM, Lee H, Choi WC, Kim KJ, Kim CH, Kang BS, et al: Crystal
structure of the human N-Myc downstream-regulated gene 2 protein
provides insight into its role as a tumor suppressor. J Biol Chem.
286:12450–12460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai J, Li R, Xu X, Zhang L, Wu S, Yang T,
Fang L, Wu J, Zhu X, Li M, et al: URGCP promotes non-small cell
lung cancer invasiveness by activating the NF-κB-MMP-9 pathway.
Oncotarget. 6:36489–36504. 2015.PubMed/NCBI
|
|
45
|
Sen T and Chatterjee A:
Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9
in breast cancer cells: Involvement of integrin receptor α5β1 in
the process. Eur J Nutr. 50:465–478. 2011. View Article : Google Scholar
|
